BOSTON (TheStreet) -- After re-reading all of the Biotech Stock Mailbag columns published in 2009, it's quite clear I wrote often about Cell Therapeutics (CTIC) and Hemispherx Biopharma (HEB). Yet I also managed to find the space to write about 88 other drug and biotech stocks -- well above the 65 companies mentioned in my 2008 Mailbag columns.
Before I get to the review of my Mailbag hits and misses from 2009, I wanted to throw out an idea for a new feature I'm thinking about for next year. I'll call it the Biotech Stock Mailbag Readers' Portfolio, or BSMRP.
Basically, the idea is to create and track a biotech stock portfolio with picks that come exclusively from readers of the Biotech Stock Mailbag. Please email me three favorite biotech stocks -- long or short -- with a very short summary of why you like (or dislike) them.
I'll collect the nominees and those stocks mentioned the most by readers -- let's say the top 12-15 stocks -- will form the basis for the BSMRP.Every month or so, perhaps more frequently, I'll devote a portion of the Mailbag to discuss the winners and losers in the portfolio. At various times of the year, perhaps I'll solicit readers' advice on stocks to sell or new ones to add. I haven't thought through all the logistics yet, but I'd like the BSMRP to be an experiment to determine if the collective wisdom of the Mailbag community can put together a winning biotech stock portfolio. Like I said, I'm still working out the details. In the meantime, send your three best biotech stock picks to email@example.com. Please put BSMRP in the subject line of your email. And look for more details about the BSMRP in January.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV